Series C · Biotech
BigHat Biosciences raises $75m Series C for antibody development
Premji Invest and DFJ Growth co-led financing to advance BigHat’s drug pipeline and experimental protein-design platform.
New investors included LG Technology Ventures and Sigmas Group. Returning backers included Amgen Ventures, Eli Lilly, Merck Global Health Innovation Fund and S32, alongside other investors.
The capital will support BHB-810, now in Phase 1, and development of BHB-299, whose clinical trial is planned for 2027. BigHat combines machine learning with laboratory experiments to design antibody medicines and generate data for subsequent designs.
Use of funds
Advance clinical pipeline programs BHB810 and BHB299
Scale autonomous experimental data generation for protein design
Funding history
Series C · This round$75M